Find disease awareness content and relevant supporting materials
Current state and future prospect of the therapeutic strategy targeting cysteinyl leukotriene metabolism in asthma.
Asthma is an allergic disorder with dominant type 2 airway inflammation, and its prevalence is increasing worldwide. Inhalation of corticosteroids is the primary treatment for asthma along with add-on drugs, including...
Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment
An estimated 300 million people are affected by asthma worldwide and the burden is likely to rise substantially in the next few decades. Estimates of the prevalence of asthma range from 7% in France and Germany to 11% in the USA...
Impact of intranasal corticosteroids on asthma outcomes in allergic rhinitis: a meta-analysis
Given the relationship between allergic rhinitis (AR) and asthma, it can be hypothesized that reducing inflammation in the upper airway with intranasal corticosteroid (INCS) medications may improve asthma outcomes.
Prevalence and management of severe asthma in primary care: an observational cohort study in Sweden (PACEHR).
Background: Severe and uncontrolled asthma is associated with increased risk of exacerbations and death. A substantial proportion of asthma patients have poor asthma control, and a concurrent COPD diagnosis often increases disease burden.
Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
Systemic/oral corticosteroids (OCS) have been used for decades in the management of acute asthma exacerbations and chronically in patients with uncontrolled severe asthma. However, while OCS are effective at treating acute exacerbations...
Development of New Therapies for Severe Asthma.
Persistent asthma has long been treated with inhaled corticosteroids (CSs), as the mainstay of therapy. However, their efficacy in patients with more severe disease is limited, which led to the incorporation of poor response to ICSs...
Montelukast 5mg Chewable Tablets
Montelukastis indicated in the treatment of asthma as add-on therapy in those patients with mild to moderate persistent asthma who are inadequately controlled on inhaled corticosteroids and in whom 'as-needed' short-acting β-agonists provide inadequate clinical control of asthma. Montelukastmay also be an alternative treatment option to low-dose inhaled corticosteroids for patients with mild persistent asthma who do not have a recent history of serious asthma attacks that required oral corticosteroid use, and who have demonstrated that they are not capable of using inhaled corticosteroids (see section 4.2) Montelukast is also indicated in the prophylaxis of asthma from in which the predominant component is exercise-induced bronchoconstriction.